N-acetylcysteine potentiates doxorubicin-induced ATM and p53 activation in ovarian cancer cells

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 211-218

  Brum, Gabriella ^a   Carbone, Thomas ^a   Still, Eric ^a   Correia, Vendita ^a   Szulak, Kevin ^a   Calianese, David ^a   Best, Charles ^a   Cammarata, Garret ^a   Higgins, Katelyn ^a   Ji, Fang ^b   Di, Wen ^b   Wan, Yinsheng ^a  

^a PROVIDENCE COLLEGE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ATM; Doxorubicin; N acetylcysteine; Ovarian cancer; P53

Indexed keywords

ACETYLCYSTEINE; ACTIN; ATM PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; HISTONE H2AX; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; PROTEIN S6; PYRROLIDINE DITHIOCARBAMATE; SERINE; TUBULIN; VIMENTIN;

ACETYLATION; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ACETYLCYSTEINE; ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE PROTEINS; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG SYNERGISM; FEMALE; FREE RADICAL SCAVENGERS; HISTONES; HUMANS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84873694439     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1680     Document Type: Article

References (42)

1. Sardao VA, Oliveira PJ, Holy J, Oliveira CR and Wallace KB: Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol 25: 227-243, 2009.
2. Hublarova P, Greplova K, Holcakova J, Vojtesek B and Hrstka R: Switching p53-dependent growth arrest to apoptosis via the inhibition of DNA damage-activated kinases. Cell Mol Biol Lett 15: 473-484, 2010.
3. Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G and Choi KS: Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24: 4765-4777, 2005. (Pubitemid 41076294)
4. Kurz EU, Douglas P and Lees-Miller SP: Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 279: 53272-53281, 2004. (Pubitemid 40051831)
5. Voisard R, Seitzer U, Baur R, Dartsch PC, Osterhues H, Hoher M and Hombach V: A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis. Int J Cardiol 51: 15-28, 1995.
6. Otsuka Y, Tanaka T, Uchida D, Noguchi Y, Saeki N, Saito Y and Tatsuno I: Roles of cyclin-dependent kinase 4 and p53 in neuronal cell death induced by doxorubicin on cerebellar granule neurons in mouse. Neurosci Lett 365: 180-185, 2004. (Pubitemid 38891778)
7. Panta GR, Kaur S, Cavin LG, Cortes ML, Mercurio F, Lothstein L, Sweatman TW, Israel M and Arsura M: ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol 24: 1823-1835, 2004. (Pubitemid 38248925)
8. Wu R, Hu TC, Rehemtulla A, Fearon ER and Cho KR: Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 17: 7359-7372, 2011.
9. Litwiniec A, Grzanka A, Helmin-Basa A, Gackowska L and Grzanka D: Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins. J Cancer Res Clin Oncol 136: 717-736, 2010.
10. Grzanka A, Grzanka D and Orlikowska M: Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines. Biochem Pharmacol 66: 1611-1617, 2003. (Pubitemid 38373353)
11. Bijman MN, van Berkel MP, van Nieuw Amerongen GP and Boven E: Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. Biochem Pharmacol 76: 707-716, 2008.
12. Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Wanebo H, Kouttab N, Chu W and Wan Y: Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. Oncol Rep 16: 907-913, 2006.
13. Albrecht-Buehler G: The phagokinetic tracks of 3T3 cells. Cell 11: 395-404, 1977.
14. Qiu L, Wang Q, Di W, Jiang Q, Schefeller E, Derby S, Wanebo H, Yan B and Wan Y: Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol 27: 823-830, 2005.
15. Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B and Wan Y: Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol 27: 1441-1448, 2005.
16. Bagriacik EU, Uslu K, Yurtcu E, Stefek M and Karasu C: Stobadine inhibits doxorubicin-induced apoptosis through a caspase-9 dependent pathway in P815 mastocytoma cells. Cell Biol Int 31: 979-984, 2007. (Pubitemid 46819068)
17. Rogalska A, Gajek A, Szwed M, Jozwiak Z and Marczak A: The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicol In Vitro 25: 1712-1720, 2011.
18. McLoon LK, Falkenberg JH, Dykstra D and Iaizzo PA: Doxorubicin chemomyectomy as a treatment for cervical dystonia: histological assessment after direct injection into the sternocleidomastoid muscle. Muscle Nerve 21: 1457-1464, 1998. (Pubitemid 28453134)
19. Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di W and Wan Y: Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol 62: 857-865, 2008.
20. Necco A, Vailati G and Colombo R: Actin behaviour in doxorubicin treatment. Cell Biol Int Rep 7: 129-134, 1983. (Pubitemid 13122421)
21. Dalledonne I, Milzani A and Colombo R: DXR depresses the alpha-actinin-induced formation of actin bundles. Cancer Biochem Biophys 13: 245-254, 1993. (Pubitemid 2013355)
22. Necco A, Usardi C, Scari G, Islam K, Melzner I and Vergani G: The effects of doxorubicin on embryonic spinal motoneurons cultured in vitro: cytoskeletal response. Cytotechnology 11: 133-141, 1993.
23. Colombo R, Necco A, Vailati G, Saracco B, Milzani A and Scari G: Doxorubicin affects actin assembly in vitro. Cell Biol Int Rep 8: 127-135, 1984. (Pubitemid 14173628)
24. Mariano R, Gonzalez B and Lewis W: Cardiac actin interactions with doxorubicin in vitro. Exp Mol Pathol 44: 7-13, 1986. (Pubitemid 16038150)
25. Jaamaa S, Af Hallstrom TM, Sankila A, Rantanen V, Koistinen H, Stenman UH, Zhang Z, Yang Z, De Marzo AM, Taari K, Ruutu M, Andersson LC and Laiho M: DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res 70: 8630-8641, 2010.
26. Alexandre J, Hu Y, Lu W, Pelicano H and Huang P: Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67: 3512-3517, 2007. (Pubitemid 46762129)
27. Kim BM, Choi YJ, Lee YH, Joe YA and Hong SH: N, N-Dimethyl phytosphingosine sensitizes HL-60/MX2, a multidrug-resistant variant of HL-60 cells, to doxorubicin-induced cytotoxicity through ROS-mediated release of cytochrome c and AIF. Apoptosis 15: 982-993, 2010.
28. Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, Greber UF and Fojo T: Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99: 10855-10860, 2002.
29. Imreh G, Norberg HV, Imreh S and Zhivotovsky B: Chromosomal breaks during mitotic catastrophe trigger gammaH2AX-ATM-p53-mediated apoptosis. J Cell Sci 124: 2951-2963, 2011.
30. Gokcimen A, Cim A, Tola HT, Bayram D, Kocak A, Ozguner F and Ayata A: Protective effect of N-acetylcysteine, caffeic acid and vitamin E on doxorubicin hepatotoxicity. Hum Exp Toxicol 26: 519-525, 2007. (Pubitemid 47224747)
31. Ashley N and Poulton J: Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling. Oncogene 28: 3880-3891, 2009.
32. Bichat F, Mouawad R, Solis-Recendez G, Khayat D and Bastian G: Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res 17: 3393-3401, 1997. (Pubitemid 27522300)
33. Grzanka A: Estimation of changes in vimentin filaments induced by etoposide and doxorubicin in human leukemia cell line K-562 by using immunofluorescence microscopy. Neoplasma 48: 285-289, 2001. (Pubitemid 32802440)
34. Grzanka A, Grzanka D and Orlikowska M: Fluorescence and ultrastructural localization of actin distribution patterns in the nucleus of HL-60 and K-562 cell lines treated with cytostatic drugs. Oncol Rep 11: 765-770, 2004.
35. Grzanka D, Marszalek A, Izdebska M, Gackowska L, Andrzej Szczepanski M and Grzanka A: Actin cytoskeleton reorganization correlates with cofilin nuclear expression and ultrastructural changes in cho aa8 cell line after apoptosis and mitotic catastrophe induction by doxorubicin. Ultrastruct Pathol 35: 130-138, 2011.
36. Maxwell SA, Cherry EM and Bayless KJ: Akt, 14-3-3zeta, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. Leuk Lymphoma 52: 849-864, 2011.
37. Akan I, Akan S, Akca H, Savas B and Ozben T: N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance. Eur J Clin Invest 34: 683-689, 2004. (Pubitemid 39423026)
38. Herman EH, Ferrans VJ, Myers CE and Van Vleet JF: Comparison of the effectiveness of (+/-)-1, 2-bis(3, 5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res 45: 276-281, 1985. (Pubitemid 15196968)
39. Kockar MC, Naziroglu M, Celik O, Tola HT, Bayram D and Koyu A: N-acetylcysteine modulates doxorubicin-induced oxidative stress and antioxidant vitamin concentrations in liver of rats. Cell Biochem Funct 28: 673-677, 2010.
40. Park ES, Kim SD, Lee MH, Lee HS, Lee IS, Sung JK and Yoon YS: Protective effects of N-acetylcysteine and selenium against doxorubicin toxicity in rats. J Vet Sci 4: 129-136, 2003.
41. Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA and Corey SJ: Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 101: 38-47, 2009.
42. Bulucu F, Oktenli C, Kenar L, Koc B, Ocal R, Karadurmus N, Inal V, Yamanel L, Sanisoglu YS and Aydin A: Detrimental effects of N-acetylcysteine plus desferoxamine combination in an experimental nephrotic syndrome model. Int J Toxicol 26: 525-532, 2007. (Pubitemid 350232908)